Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 12/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 12/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13790333 | 0.83 | CYP1A1 (0.71) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL13790243 | 0.83 | CYP1A1 (0.71) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL8367958 | 0.83 | CYP1A1 (0.71) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL7567897 | 0.83 | CYP1A1 (0.71) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL20460722 | 0.83 | CYP1A1 (0.41) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL24299463 | 0.78 | CYP3A4 (0.37) | CYP1A1CYP1B1CYP1A2ALDH1A1MAPT | |
| SCHEMBL2622608 | 0.78 | CYP1A1 (0.59) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL9967789 | 0.78 | TUBB4A (0.55) | CYP1A1CYP1B1CYP1A2ALDH1A1MAPT | |
| SCHEMBL16638503 | 0.78 | CYP1A1 (0.38) | CYP1A1CYP1B1CYP1A2ALDH1A1FBP1 | |
| SCHEMBL9967772 | 0.78 | ALDH1A1 (0.44) | CYP1A1CYP1B1CYP1A2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | CYP1A1 603/4885CYP1B1 390/4885CYP1A2 862/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | CYP1A1 603/4885CYP1B1 390/4885CYP1A2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.